<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070494</url>
  </required_header>
  <id_info>
    <org_study_id>MURA2019/1116</org_study_id>
    <nct_id>NCT05070494</nct_id>
  </id_info>
  <brief_title>Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients</brief_title>
  <acronym>Enhance</acronym>
  <official_title>Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients: Randomized Controlled Trial (Enhance Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bhumirajanagarindra Kidney Institute, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a randomized controlled trial to investigate the immune response of influenza&#xD;
      vaccines when doses were increased. and a second vaccination together with an increase in the&#xD;
      amount of vaccine in patients with chronic kidney disease receiving hemodialysis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patients with chronic kidney disease undergoing dialysis will be examined by an&#xD;
           internist.&#xD;
&#xD;
        2. Collect the necessary basic information of patients who agree to participate in the&#xD;
           treatment.&#xD;
&#xD;
        3. Patients will be randomized to be divided into 3 groups: those who will receive an&#xD;
           standard dose of influenza vaccine, those who will receive double standard dose of&#xD;
           influenza vaccine (double-dose) and those who will receive double standard dose of&#xD;
           influenza vaccine and Six months after the first dose of vaccination&#xD;
           (double-booster-dose), 50 people per group.&#xD;
&#xD;
        4. Non-dialysis volunteers will be invited to participate in the research. to be a control&#xD;
           group of 25 people&#xD;
&#xD;
        5. Patients with chronic kidney disease and volunteers will receive basic laboratory blood&#xD;
           tests.&#xD;
&#xD;
        6. Patients with chronic kidney disease and volunteers will be vaccinated against&#xD;
           influenza. shoulder muscle area according to random groups The details of using Influvac&#xD;
           vaccine of that year are produced by Abbott.&#xD;
&#xD;
        7. Patients with chronic kidney disease and volunteers are asked about the potential side&#xD;
           effects of vaccination. according to research guidelines both systemic side effects and&#xD;
           injection site Each time receiving hemodialysis 3 times a week for 2 weeks after&#xD;
           vaccination&#xD;
&#xD;
        8. Patients with chronic kidney disease and volunteers were asked about the onset of&#xD;
           symptoms of respiratory infection throughout the 12-month study period after&#xD;
           vaccination.&#xD;
&#xD;
        9. Patients will receive a blood test to check their immune response to influenza vaccine.&#xD;
           (Hemagglutination inhibition assays and activation and/or exhaustion T cell markers, T&#xD;
           cell subpopulation by flow cytometry) at 1, 6, 7 and 12 months after influenza&#xD;
           vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare proportion of seroprotection of different doses of influenza vaccine in hemodialysis patients at month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will receive a blood test to check their immune response to influenza vaccine. (Hemagglutination inhibition assays and activation and/or exhaustion T cell markers, T cell subpopulation by flow cytometry) at month 12 after influenza vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the prevention of influenza virus infection in different doses of influenza vaccination.</measure>
    <time_frame>12 months of data collection</time_frame>
    <description>to compare incidence rate of influenza infection in different doses of influenza</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>ESRD</condition>
  <condition>Influenza Vaccine</condition>
  <condition>Seroprotection</condition>
  <arm_group>
    <arm_group_label>้healthy subject with standard dose trivalent influenza vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>้healthy volunteer that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESRD patient with standard dose trivalent influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ESRD patient that received Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) ( 0.5 ml : 15 mcg/strain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESRD patient with double dose trivalent influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) total 1 ml ( 1 ml /(30 mcg/strain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESRD patient with double dose - booster trivalent influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESRD patient that received Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) and booster with Egg-derived double dose trivalent influenza vaccine (surface antigen, inactivated) ( 1 ml /(30 mcg/strain) at next 6 months after first dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)</intervention_name>
    <description>study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)</description>
    <arm_group_label>ESRD patient with double dose - booster trivalent influenza vaccine</arm_group_label>
    <arm_group_label>ESRD patient with double dose trivalent influenza vaccine</arm_group_label>
    <arm_group_label>ESRD patient with standard dose trivalent influenza vaccine</arm_group_label>
    <arm_group_label>้healthy subject with standard dose trivalent influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Received kidney replacement therapy with dialysis for more than 1 month.&#xD;
&#xD;
          -  Hemodialysis at least 3 times a week&#xD;
&#xD;
          -  (Kt/v) greater than 1.2&#xD;
&#xD;
          -  Never received an organ transplant.&#xD;
&#xD;
          -  Life expectancy of more than 1 year&#xD;
&#xD;
          -  Research participants or representatives are welcome to join the project by signing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any vaccinations in the 4 weeks prior to the study.&#xD;
&#xD;
          -  History of receiving influenza vaccine 6 months before entering this study.&#xD;
&#xD;
          -  History of allergy to flu vaccine or allergic to egg white&#xD;
&#xD;
          -  Fever or headache, muscle pain (influenza-like illness) 3 days before vaccination&#xD;
&#xD;
          -  Thrombocytopenia&#xD;
&#xD;
          -  On immunosuppressive drug (Prednisolone 15 mg daily or equivalent for two weeks in a&#xD;
             row in the previous 3 months) or immunocompromised patient&#xD;
&#xD;
          -  Patient or family history of having had Guillain-Barre disease. (Guillain-Barre&#xD;
             syndrome)&#xD;
&#xD;
          -  The research participant or his representative refuses or requests to withdraw.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Angsana Phuphuakrat, MD, PhD</last_name>
    <phone>6622011581</phone>
    <email>angsana.phu@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Angsana Phuphuakrat</name>
      <address>
        <city>Ratchathewi</city>
        <state>ฺBangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angsana Phuphuakrat, MD, PhD</last_name>
      <phone>6622011581</phone>
      <email>angsana.phu@mahidol.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://immunityageing.biomedcentral.com/articles/10.1186/1742-4933-9-19</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5916a2.htm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.nejm.org/doi/full/10.1056/nejmoa1315727</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Chou CY, Wang SM, Liang CC, Chang CT, Liu JH, Wang IK, Hsiao LC, Muo CH, Huang CC, Wang RY. Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study. Medicine (Baltimore). 2014 Dec;93(27):e174. doi: 10.1097/MD.0000000000000174.</citation>
    <PMID>25501062</PMID>
  </reference>
  <reference>
    <citation>Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S5-11. doi: 10.2215/CJN.05980809. Review.</citation>
    <PMID>19996006</PMID>
  </reference>
  <reference>
    <citation>Viasus D, Garcia-Vidal C, Cruzado JM, Adamuz J, Verdaguer R, Manresa F, Dorca J, Gudiol F, Carratalà J. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant. 2011 Sep;26(9):2899-906. doi: 10.1093/ndt/gfq798. Epub 2011 Jan 27.</citation>
    <PMID>21273232</PMID>
  </reference>
  <reference>
    <citation>Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001 Dec;120(6):1883-7.</citation>
    <PMID>11742917</PMID>
  </reference>
  <reference>
    <citation>Cohen G, Hörl WH. Immune dysfunction in uremia&amp;#8212;an update. Toxins (Basel). 2012 Oct 24;4(11):962-90. doi: 10.3390/toxins4110962. Review.</citation>
    <PMID>23202302</PMID>
  </reference>
  <reference>
    <citation>Girndt M, Sester M, Sester U, Kaul H, Köhler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl. 2001 Feb;78:S206-11. Review.</citation>
    <PMID>11169012</PMID>
  </reference>
  <reference>
    <citation>Anding K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant. 2003 Oct;18(10):2067-73.</citation>
    <PMID>13679482</PMID>
  </reference>
  <reference>
    <citation>Lim WH, Kireta S, Leedham E, Russ GR, Coates PT. Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int. 2007 Nov;72(9):1138-48. Epub 2007 Aug 29.</citation>
    <PMID>17728708</PMID>
  </reference>
  <reference>
    <citation>Sester U, Sester M, Hauk M, Kaul H, Köhler H, Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant. 2000 Aug;15(8):1217-23.</citation>
    <PMID>10910448</PMID>
  </reference>
  <reference>
    <citation>Fernández-Fresnedo G, Ramos MA, González-Pardo MC, de Francisco AL, López-Hoyos M, Arias M. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant. 2000 Apr;15(4):502-10.</citation>
    <PMID>10727545</PMID>
  </reference>
  <reference>
    <citation>Meier P, Golshayan D, Blanc E, Pascual M, Burnier M. Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol. 2009 Jun;20(6):1368-84. doi: 10.1681/ASN.2008070734. Epub 2009 Apr 30. Retraction in: J Am Soc Nephrol. 2014 Mar;25(3):645.</citation>
    <PMID>19406979</PMID>
  </reference>
  <reference>
    <citation>Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, Yen TH, Morisky DE, Huang CC, Sung FC. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One. 2013;8(3):e58317. doi: 10.1371/journal.pone.0058317. Epub 2013 Mar 13.</citation>
    <PMID>23516462</PMID>
  </reference>
  <reference>
    <citation>McGrath LJ, Kshirsagar AV, Cole SR, Wang L, Weber DJ, Stürmer T, Brookhart MA. Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med. 2012 Apr 9;172(7):548-54. doi: 10.1001/archinternmed.2011.2238.</citation>
    <PMID>22493462</PMID>
  </reference>
  <reference>
    <citation>Gilbertson DT, Unruh M, McBean AM, Kausz AT, Snyder JJ, Collins AJ. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int. 2003 Feb;63(2):738-43.</citation>
    <PMID>12631142</PMID>
  </reference>
  <reference>
    <citation>Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818-25.</citation>
    <PMID>26247435</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep. 2013 Sep 20;62(RR-07):1-43. Erratum in: MMWR Recomm Rep. 2013 Nov 15;62(45):906.</citation>
    <PMID>24048214</PMID>
  </reference>
  <reference>
    <citation>Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):309-18. doi: 10.1093/cid/cit816. Erratum in: Clin Infect Dis. 2014 Jul 1;59(1):144.</citation>
    <PMID>24421306</PMID>
  </reference>
  <reference>
    <citation>DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine. 2015 Aug 26;33(36):4565-71. doi: 10.1016/j.vaccine.2015.07.003. Epub 2015 Jul 14.</citation>
    <PMID>26187260</PMID>
  </reference>
  <reference>
    <citation>Rautenberg P, Proppe D, Schütte A, Ullmann U. Influenza subtype-specific immunoglobulin A and G responses after booster versus one double-dose vaccination in hemodialysis patients. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):897-900.</citation>
    <PMID>2512137</PMID>
  </reference>
  <reference>
    <citation>Liao Z, Xu X, Liang Y, Xiong Y, Chen R, Ni J. Effect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: A systematic literature review and meta-analysis. Hum Vaccin Immunother. 2016 Nov;12(11):2909-2915. Epub 2016 Jul 8. Review.</citation>
    <PMID>27392026</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Angsana Phuphuakrat</investigator_full_name>
    <investigator_title>Angsana Phuphuakrat</investigator_title>
  </responsible_party>
  <keyword>ESRD</keyword>
  <keyword>Influenza vaccine</keyword>
  <keyword>double dose Influenza vaccine</keyword>
  <keyword>double dose booster Influenza vaccine</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

